Repairing the basic defect in cystic fibrosis - One approach is not enough

FEBS Journal

Volumn 283, Issue 2, 2016, Pages 246-264

  Farinha, Carlos M ^a   Matos, Paulo ^a,b  

^a UNIVERSITY OF LISBON   (Portugal)

^b NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

Author keywords

bypass approaches; correctors; cystic fibrosis; cystic fibrosis transmembrane conductance regulator; novel therapies; potentiators

Indexed keywords

ATALUREN; CHLORIDE; CHLORIDE CHANNEL; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPIGALLOCATECHIN GALLATE; EPITHELIAL SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; FOSTAMATINIB; GENTAMICIN; IVACAFTOR; IVACAFTOR PLUS LUMACAFTOR; LIPOSOME; LUMACAFTOR; MERCAPTAMINE; N (3,5 DIAMINO 6 CHLOROPYRAZINE 2 CARBONYL) N' 4 [4 (2,3 DIHYDROXYPROPOXY)PHENYL]BUTYLGUANIDINE METHANESULFONATE; PLASMID DNA; PROTEIN KINASE SYK; PYRAZINE DERIVATIVE; QUINAZOLINE DERIVATIVE; TEZACAFTOR; UNCLASSIFIED DRUG; VRT 532; CFTR PROTEIN, HUMAN;

AUTOPHAGY; CELL MIGRATION; CFTR GENE; CHLORIDE TRANSPORT; CYSTIC FIBROSIS; DRUG MECHANISM; GENE MUTATION; GENE THERAPY; GENETIC TRANSCRIPTION; HUMAN; LUNG FUNCTION; MULTICENTER STUDY (TOPIC); NONHUMAN; NONSENSE MEDIATED MRNA DECAY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEIN TRANSPORT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SODIUM ABSORPTION; STOP CODON; TEMPERATURE SENSITIVITY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOPHYSIOLOGY; PROCEDURES;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; GENETIC THERAPY; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT;

EID: 84969373509     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13531     Document Type: Review

References (136)

1. Bobadilla JL, Macek M Jr, Fine JP, &, Farrell PM, (2002) Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 19, 575-606.
2. O'Sullivan BP, &, Freedman SD, (2009) Cystic fibrosis. Lancet 373, 1891-1904.
3. Riordan JR, (2005) Assembly of functional CFTR chloride channels. Annu Rev Physiol 67, 701-718.
4. Bell SC, De Boeck K, &, Amaral MD, (2015) New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther 145, 19-34.
5. Amaral MD, &, Farinha CM, (2013) Rescuing mutant CFTR: a multi-task approach to a better outcome in treating cystic fibrosis. Curr Pharm Des 19, 3497-3508.
6. Linde L, Boelz S, Neu-Yilik G, Kulozik AE, &, Kerem B, (2007a) The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells. Eur J Hum Genet 15, 1156-1162.
7. Raynal C, Baux D, Theze C, Bareil C, Taulan M, Roux AF, Claustres M, Tuffery-Giraud S, &, des Georges M, (2013) A classification model relative to splicing for variants of unknown clinical significance: application to the CFTR gene. Hum Mutat 34, 774-784.
8. Swiatecka-Urban A, Brown A, Moreau-Marquis S, Renuka J, Coutermarsh B, Barnaby R, Karlson KH, Flotte TR, Fukuda M, Langford GM, et al,. (2005) The short apical membrane half-life of rescued {Delta}F508-cystic fibrosis transmembrane conductance regulator (CFTR) results from accelerated endocytosis of {Delta}F508-CFTR in polarized human airway epithelial cells. J Biol Chem 280, 36762-36772.
9. Moniz S, Sousa M, Moraes BJ, Mendes AI, Palma M, Barreto C, Fragata JI, Amaral MD, &, Matos P, (2013) HGF stimulation of Rac1 signaling enhances pharmacological correction of the most prevalent cystic fibrosis mutant F508del-CFTR. ACS Chem Biol 8, 432-442.
10. Okiyoneda T, Barriere H, Bagdany M, Rabeh WM, Du K, Hohfeld J, Young JC, &, Lukacs GL, (2010) Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329, 805-810.
11. Ramalho AS, Lewandowska MA, Farinha CM, Mendes F, Goncalves J, Barreto C, Harris A, &, Amaral MD, (2009) Deletion of CFTR translation start site reveals functional isoforms of the protein in CF patients. Cell Physiol Biochem 24, 335-346.
12. Chu CS, Trapnell BC, Curristin SM, Cutting GR, &, Crystal RG, (1992) Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis. J Clin Invest 90, 785-790.
13. Zhang L, Button B, Gabriel SE, Burkett S, Yan Y, Skiadopoulos MH, Dang YL, Vogel LN, McKay T, Mengos A, et al,. (2009) CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 7, e1000155.
14. Griesenbach U, &, Alton EW, & UK Cystic Fibrosis Gene Therapy Consortium. (2009) Gene transfer to the lung: lessons learned from more than 2 decades of CF gene therapy. Adv Drug Deliv Rev. 61, 128-139.
15. Alton EW, Armstrong DK, Ashby D, Bayfield KJ, Bilton D, Bloomfield EV, Boyd AC, Brand J, Buchan R, Calcedo R, et al,. (2015) Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 3, 684-691.
16. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, &, Welsh MJ, (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761-764.
17. Farinha CM, King-Underwood J, Sousa M, Correia AR, Henriques BJ, Roxo-Rosa M, Da Paula AC, Williams J, Hirst S, Gomes CM, et al,. (2013a) Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction. Chem Biol 20, 943-955.
18. Roxo-Rosa M, Xu Z, Schmidt A, Neto M, Cai Z, Soares CM, Sheppard DN, &, Amaral MD, (2006) Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms. Proc Natl Acad Sci USA 103, 17891-17896.
19. Cutting GR, (2015) Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet 16, 45-56.
20. Hermann T, (2007) Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci 64, 1841-1852.
21. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, &, Sorscher EJ, (1997) Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 3, 1280-1284.
22. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, Yaacov Y, Virgilis D, Neu-Yilik G, Kulozik AE, Kerem E, et al,. (2007b) Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 117, 683-692.
23. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, &, Bedwell DM, (2008) PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc Natl Acad Sci USA 105, 2064-2069.
24. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, Aviram M, Cohen M, Armoni S, Yaakov Y, Pugatsch T, et al,. (2011) Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur Respir J 38, 59-69.
25. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, et al,. (2014) Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2, 539-547.
26. Ryan NJ, (2014) Ataluren: first global approval. Drugs 74, 1709-1714.
27. Sato S, Ward CL, Krouse ME, Wine JJ, &, Kopito RR, (1996) Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 271, 635-638.
28. Amaral MD, (2004) CFTR and chaperones: processing and degradation. J Mol Neurosci 23, 41-48.
29. Balch WE, Roth DM, &, Hutt DM, (2011) Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol 3, a004499.
30. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, et al,. (2006) Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290, L1117-L1130.
31. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al,. (2011) Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 108, 18843-18848.
32. Clancy JP, Rowe SM, Accurso FJ, Aitken ML, Amin RS, Ashlock MA, Ballmann M, Boyle MP, Bronsveld I, Campbell PW, et al,. (2011) Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12-18.
33. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, &, Rodman D, (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2, 527-538.
34. Wang Y, Bartlett MC, Loo TW, &, Clarke DM, (2006) Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones. Mol Pharmacol 70, 297-302.
35. Wang Y, Loo TW, Bartlett MC, &, Clarke DM, (2007a) Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones. Mol Pharmacol 71, 751-758.
36. Pedemonte N, Tomati V, Sondo E, &, Galietta LJ, (2010) Influence of cell background on pharmacological rescue of mutant CFTR. Am J Physiol Cell Physiol 298, C866-C874.
37. He L, Kota P, Aleksandrov AA, Cui L, Jensen T, Dokholyan NV, &, Riordan JR, (2012) Correctors of {Delta}F508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J 27, 536-545.
38. Okiyoneda T, Veit G, Dekkers JF, Bagdany M, Soya N, Xu H, Roldan A, Verkman AS, Kurth M, Simon A, et al,. (2013) Mechanism-based corrector combination restores DeltaF508-CFTR folding and function. Nat Chem Biol 9, 444-454.
39. Snodgrass SM, Cihil KM, Cornuet PK, Myerburg MM, &, Swiatecka-Urban A, (2013) Tgf-beta1 inhibits Cftr biogenesis and prevents functional rescue of DeltaF508-Cftr in primary differentiated human bronchial epithelial cells. PLoS One 8, e63167.
40. Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, et al,. (2005) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353, 1443-1453.
41. Wang Y, Loo TW, Bartlett MC, &, Clarke DM, (2007b) Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem J 406, 257-263.
42. Ramachandran S, Karp PH, Jiang P, Ostedgaard LS, Walz AE, Fisher JT, Keshavjee S, Lennox KA, Jacobi AM, Rose SD, et al,. (2012) A microRNA network regulates expression and biosynthesis of wild-type and DeltaF508 mutant cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci U S A 109, 13362-13367.
43. Phuan PW, Veit G, Tan J, Roldan A, Finkbeiner WE, Lukacs GL, &, Verkman AS, (2014) Synergy-based small-molecule screen using a human lung epithelial cell line yields DeltaF508-CFTR correctors that augment VX-809 maximal efficacy. Mol Pharmacol 86, 42-51.
44. Nieddu E, Pollarolo B, Mazzei MT, Anzaldi M, Schenone S, Pedemonte N, Pesce E, Galietta LJ, &, Mazzei M, (2014) The search for a common structural moiety among selected pharmacological correctors of the mutant CFTR chloride channel. Future Med Chem 6, 1857-1868.
45. Ramachandran S, Osterhaus SR, Karp PH, Welsh MJ, &, McCray PB Jr, (2014) A genomic signature approach to rescue DeltaF508-cystic fibrosis transmembrane conductance regulator biosynthesis and function. Am J Respir Cell Mol Biol 51, 354-362.
46. Awatade NT, Uliyakina I, Farinha CM, Clarke LA, Mendes K, Sole A, Pastor J, Ramos MM, &, Amaral MD, (2015) Measurements of functional responses in human primary lung cells as a basis for personalized therapy for cystic fibrosis. EBioMedicine 2, 147-153.
47. Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, et al,. (2013) A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med 19, 939-945.
48. Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, Robins LI, Dicus CW, Willenbring D, Nantz MH, et al,. (2005a) Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 67, 1797-1807.
49. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, &, Verkman AS, (2005b) Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 115, 2564-2571.
50. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al,. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 106, 18825-18830.
51. Yu H, Burton B, Huang CJ, Worley J, Cao D, Johnson JP Jr, Urrutia A, Joubran J, Seepersaud S, Sussky K, et al,. (2012) Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst Fibr 11, 237-245.
52. Van Goor F, Yu H, Burton B, &, Hoffman BJ, (2014) Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros 13, 29-36.
53. Csanady L, &, Torocsik B, (2014) Structure-activity analysis of a CFTR channel potentiator: distinct molecular parts underlie dual gating effects. J Gen Physiol 144, 321-336.
54. VERTEX (2014) Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation (http://investors.vrtx.com/releasedetail.cfm?ReleaseID=856185) (Accessed 21 September 2015).
55. Favia M, Mancini MT, Bezzerri V, Guerra L, Laselva O, Abbattiscianni AC, Debellis L, Reshkin SJ, Gambari R, Cabrini G, et al,. (2014) Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. Am J Physiol Lung Cell Mol Physiol 307, L48-L61.
56. Cholon DM, Quinney NL, Fulcher ML, Esther CR Jr, Das J, Dokholyan NV, Randell SH, Boucher RC, &, Gentzsch M, (2014) Potentiator ivacaftor abrogates pharmacological correction of DeltaF508 CFTR in cystic fibrosis. Sci Transl Med 6, 246ra96.
57. Veit G, Avramescu RG, Perdomo D, Phuan PW, Bagdany M, Apaja PM, Borot F, Szollosi D, Wu YS, Finkbeiner WE, et al,. (2014) Some gating potentiators, including VX-770, diminish DeltaF508-CFTR functional expression. Sci Transl Med 6, 246ra97.
58. Kim Chiaw P, Wellhauser L, Huan LJ, Ramjeesingh M, &, Bear CE, (2010) A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 78, 411-418.
59. Farinha CM, Sousa M, Canato S, Schmidt A, Uliyakina I, &, Amaral MD, (2015) Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect 3, e00152.
60. He L, Aleksandrov AA, Serohijos AW, Hegedus T, Aleksandrov LA, Cui L, Dokholyan NV, &, Riordan JR, (2008) Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating. J Biol Chem 283, 26383-26390.
61. Protasevich I, Yang Z, Wang C, Atwell S, Zhao X, Emtage S, Wetmore D, Hunt JF, &, Brouillette CG, (2010) Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1. Protein Sci 19, 1917-1931.
62. Wang C, Protasevich I, Yang Z, Seehausen D, Skalak T, Zhao X, Atwell S, Spencer Emtage J, Wetmore DR, Brouillette CG, et al,. (2010a) Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis. Protein Sci 19, 1932-1947.
63. Wang XR, &, Li C, (2014) Decoding F508del misfolding in cystic fibrosis. Biomolecules 4, 498-509.
64. Rabeh WM, Bossard F, Xu H, Okiyoneda T, Bagdany M, Mulvihill CM, Du K, di Bernardo S, Liu Y, Konermann L, et al,. (2012) Correction of both NBD1 energetics and domain interface is required to restore DeltaF508 CFTR folding and function. Cell 148, 150-163.
65. Mendoza JL, Schmidt A, Li Q, Nuvaga E, Barrett T, Bridges RJ, Feranchak AP, Brautigam CA, &, Thomas PJ, (2012) Requirements for efficient correction of DeltaF508 CFTR revealed by analyses of evolved sequences. Cell 148, 164-174.
66. Hoelen H, Kleizen B, Schmidt A, Richardson J, Charitou P, Thomas PJ, &, Braakman I, (2010) The primary folding defect and rescue of DeltaF508 CFTR emerge during translation of the mutant domain. PLoS One 5, e15458.
67. Farinha CM, Matos P, &, Amaral MD, (2013b) Control of CFTR membrane trafficking: not just from the ER to the Golgi. FEBS J 280, 4396-4406.
68. Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K, Bache KG, Papsin B, Zerangue N, Stenmark H, et al,. (2004) Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. J Cell Biol 164, 923-933.
69. Glozman R, Okiyoneda T, Mulvihill CM, Rini JM, Barriere H, &, Lukacs GL, (2009) N-glycans are direct determinants of CFTR folding and stability in secretory and endocytic membrane traffic. J Cell Biol 184, 847-862.
70. Lukacs GL, Segal G, Kartner N, Grinstein S, &, Zhang F, (1997) Constitutive internalization of cystic fibrosis transmembrane conductance regulator occurs via clathrin-dependent endocytosis and is regulated by protein phosphorylation. Biochem J 328, 353-361.
71. Apaja PM, Xu H, &, Lukacs GL, (2010) Quality control for unfolded proteins at the plasma membrane. J Cell Biol 191, 553-570.
72. Holleran JP, Zeng J, Frizzell RA, &, Watkins SC, (2013) Regulated recycling of mutant CFTR is partially restored by pharmacological treatment. J Cell Sci 126, 2692-2703.
73. Jurkuvenaite A, Chen L, Bartoszewski R, Goldstein R, Bebok Z, Matalon S, &, Collawn JF, (2010) Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am J Respir Cell Mol Biol 42, 363-372.
74. Cholon DM, O'Neal WK, Randell SH, Riordan JR, &, Gentzsch M, (2010) Modulation of endocytic trafficking and apical stability of CFTR in primary human airway epithelial cultures. Am J Physiol Lung Cell Mol Physiol 298, L304-L314.
75. Swiatecka-Urban A, Duhaime M, Coutermarsh B, Karlson KH, Collawn J, Milewski M, Cutting GR, Guggino WB, Langford G, &, Stanton BA, (2002) PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator. J Biol Chem 277, 40099-40105.
76. Wolde M, Fellows A, Cheng J, Kivenson A, Coutermarsh B, Talebian L, Karlson K, Piserchio A, Mierke DF, Stanton BA, et al,. (2007) Targeting CAL as a negative regulator of DeltaF508-CFTR cell-surface expression: an RNA interference and structure-based mutagenetic approach. J Biol Chem 282, 8099-8109.
77. Cheng J, Wang H, &, Guggino WB, (2005) Regulation of cystic fibrosis transmembrane regulator trafficking and protein expression by a Rho family small GTPase TC10. J Biol Chem 280, 3731-3739.
78. Chang XB, Mengos A, Hou YX, Cui L, Jensen TJ, Aleksandrov A, Riordan JR, &, Gentzsch M, (2008) Role of N-linked oligosaccharides in the biosynthetic processing of the cystic fibrosis membrane conductance regulator. J Cell Sci 121, 2814-2823.
79. Cheng J, Wang H, &, Guggino WB, (2004) Modulation of mature cystic fibrosis transmembrane regulator protein by the PDZ domain protein CAL. J Biol Chem 279, 1892-1898.
80. Cushing PR, Fellows A, Villone D, Boisguerin P, &, Madden DR, (2008) The relative binding affinities of PDZ partners for CFTR: a biochemical basis for efficient endocytic recycling. Biochemistry 47, 10084-10098.
81. Favia M, Guerra L, Fanelli T, Cardone RA, Monterisi S, Di Sole F, Castellani S, Chen M, Seidler U, Reshkin SJ, et al,. (2010) Na+/H+ exchanger regulatory factor 1 overexpression-dependent increase of cytoskeleton organization is fundamental in the rescue of F508del cystic fibrosis transmembrane conductance regulator in human airway CFBE41o- cells. Mol Biol Cell 21, 73-86.
82. Guerra L, Fanelli T, Favia M, Riccardi SM, Busco G, Cardone RA, Carrabino S, Weinman EJ, Reshkin SJ, Conese M, et al,. (2005) Na+/H+ exchanger regulatory factor isoform 1 overexpression modulates cystic fibrosis transmembrane conductance regulator (CFTR) expression and activity in human airway 16HBE14o- cells and rescues DeltaF508 CFTR functional expression in cystic fibrosis cells. J Biol Chem 280, 40925-40933.
83. Castellani S, Guerra L, Favia M, Di Gioia S, Casavola V, &, Conese M, (2012) NHERF1 and CFTR restore tight junction organisation and function in cystic fibrosis airway epithelial cells: role of ezrin and the RhoA/ROCK pathway. Lab Invest 92, 1527-1540.
84. Loureiro CA, Matos AM, Dias-Alves Â, Pereira JF, Uliyakina I, Barros P, Amaral MD, &, Matos P, (2015) A NHERF1 PDZ domain switch prevents CHIP Ub ligase-mediated peripheral protein quality control retaining misfolded CFTR at the cell surface. Sci Signal 8, ra48.
85. Haggie PM, Kim JK, Lukacs GL, &, Verkman AS, (2006) Tracking of quantum dot-labeled CFTR shows near immobilization by C-terminal PDZ interactions. Mol Biol Cell 17, 4937-4945.
86. Short DB, Trotter KW, Reczek D, Kreda SM, Bretscher A, Boucher RC, Stutts MJ, &, Milgram SL, (1998) An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. J Biol Chem 273, 19797-19801.
87. Li J, Dai Z, Jana D, Callaway DJ, &, Bu Z, (2005) Ezrin controls the macromolecular complexes formed between an adapter protein Na+/H+ exchanger regulatory factor and the cystic fibrosis transmembrane conductance regulator. J Biol Chem 280, 37634-37643.
88. Ganeshan R, Nowotarski K, Di A, Nelson DJ, &, Kirk KL, (2007) CFTR surface expression and chloride currents are decreased by inhibitors of N-WASP and actin polymerization. Biochim Biophys Acta 1773, 192-200.
89. Monterisi S, Casavola V, &, Zaccolo M, (2013) Local modulation of cystic fibrosis conductance regulator: cytoskeleton and compartmentalized cAMP signalling. Br J Pharmacol 169, 1-9.
90. Monterisi S, Favia M, Guerra L, Cardone RA, Marzulli D, Reshkin SJ, Casavola V, &, Zaccolo M, (2012) CFTR regulation in human airway epithelial cells requires integrity of the actin cytoskeleton and compartmentalized cAMP and PKA activity. J Cell Sci 125, 1106-1117.
91. Nakamura T, Sakai K, Nakamura T, &, Matsumoto K, (2011) Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 26 (Suppl 1), 188-202.
92. Panganiban RA, &, Day RM, (2011) Hepatocyte growth factor in lung repair and pulmonary fibrosis. Acta Pharmacol Sin 32, 12-20.
93. Chakraborty S, Chopra P, Hak A, Dastidar SG, &, Ray A, (2013) Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis. Expert Opin Investig Drugs 22, 499-515.
94. Smyth EC, Sclafani F, &, Cunningham D, (2014) Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 7, 1001-1014.
95. Guggino WB, &, Stanton BA, (2006) New insights into cystic fibrosis: molecular switches that regulate CFTR. Nat Rev Mol Cell Biol 7, 426-436.
96. Kunzelmann K, &, Mehta A, (2013) CFTR: a hub for kinases and cross-talk of cAMP and Ca. FEBS J 280, 4417-4429.
97. Luz S, Kongsuphol P, Mendes AI, Romeiras F, Sousa M, Schreiber R, Matos P, Jordan P, Mehta A, Amaral MD, et al,. (2011) Contribution of casein kinase 2 and spleen tyrosine kinase to CFTR trafficking and protein kinase A-induced activity. Mol Cell Biol 31, 4392-4404.
98. Mendes AI, Matos P, Moniz S, Luz S, Amaral MD, Farinha CM, &, Jordan P, (2011) Antagonistic regulation of CFTR cell surface expression by protein kinases WNK4 and spleen tyrosine kinase. Mol Cell Biol 31, 4076-4086.
99. Geahlen RL, (2014) Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci 35, 414-422.
100. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, &, Brahn E, (2007) Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 124, 244-257.
101. Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A, Jia ZJ, Pandey A, Baker D, et al,. (2012) Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. J Pharmacol Exp Ther 340, 350-359.
102. Liao C, Hsu J, Kim Y, Hu DQ, Xu D, Zhang J, Pashine A, Menke J, Whittard T, Romero N, et al,. (2013) Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy. Arthritis Res Ther 15, R146.
103. Currie KS, Kropf JE, Lee T, Blomgren P, Xu J, Zhao Z, Gallion S, Whitney JA, Maclin D, Lansdon EB, et al,. (2014) Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem 57, 3856-3873.
104. Weinblatt ME, Kavanaugh A, Genovese MC, Jones DA, Musser TK, Grossbard EB, &, Magilavy DB, (2013) Effects of fostamatinib (R788), an oral spleen tyrosine kinase inhibitor, on health-related quality of life in patients with active rheumatoid arthritis: analyses of patient-reported outcomes from a randomized, double-blind, placebo-controlled trial. J Rheumatol 40, 369-378.
105. Pathare G, Hoenderop JG, Bindels RJ, &, San-Cristobal P, (2013) A molecular update on pseudohypoaldosteronism type II. Am J Physiol Renal Physiol 305, F1513-F1520.
106. Wang WH, Yue P, Sun P, &, Lin DH, (2010b) Regulation and function of potassium channels in aldosterone-sensitive distal nephron. Curr Opin Nephrol Hypertens 19, 463-470.
107. Caohuy H, Yang Q, Eudy Y, Ha TA, Xu AE, Glover M, Frizzell RA, Jozwik C, &, Pollard HB, (2014) Activation of 3-phosphoinositide-dependent kinase 1 (PDK1) and serum- and glucocorticoid-induced protein kinase 1 (SGK1) by short-chain sphingolipid C4-ceramide rescues the trafficking defect of DeltaF508-cystic fibrosis transmembrane conductance regulator (DeltaF508-CFTR). J Biol Chem 289, 35953-35968.
108. Guilbault C, Wojewodka G, Saeed Z, Hajduch M, Matouk E, De Sanctis JB, &, Radzioch D, (2009) Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol 41, 100-106.
109. Guilbault C, De Sanctis JB, Wojewodka G, Saeed Z, Lachance C, Skinner TA, Vilela RM, Kubow S, Lands LC, Hajduch M, et al,. (2008) Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol 38, 47-56.
110. Teichgraber V, Ulrich M, Endlich N, Riethmuller J, Wilker B, De Oliveira-Munding CC, van Heeckeren AM, Barr ML, von Kurthy G, Schmid KW, et al,. (2008) Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat Med 14, 382-391.
111. Becker KA, Grassme H, Zhang Y, &, Gulbins E, (2010) Ceramide in Pseudomonas aeruginosa infections and cystic fibrosis. Cell Physiol Biochem 26, 57-66.
112. Luz S, Cihil KM, Brautigan DL, Amaral MD, Farinha CM, &, Swiatecka-Urban A, (2014) LMTK2 mediated phosphorylation regulates CFTR endocytosis in human airway epithelial cells. J Biol Chem 289, 15080-15093.
113. Kunzelmann K, &, Schreiber R, (1999) CFTR, a regulator of channels. J Membr Biol 168, 1-8.
114. Kunzelmann K, Schreiber R, &, Boucherot A, (2001) Mechanisms of the inhibition of epithelial Na(+) channels by CFTR and purinergic stimulation. Kidney Int 60, 455-461.
115. Suaud L, Yan W, Carattino MD, Robay A, Kleyman TR, &, Rubenstein RC, (2007) Regulatory interactions of N1303K-CFTR and ENaC in Xenopus oocytes: evidence that chloride transport is not necessary for inhibition of ENaC. Am J Physiol Cell Physiol 292, C1553-C1561.
116. - concentration. EMBO Rep 2, 1047-1051.
117. Kunzelmann K, &, Mall M, (2001) Pharmacotherapy of the ion transport defect in cystic fibrosis. Clin Exp Pharmacol Physiol 28, 857-867.
118. App EM, King M, Helfesrieder R, Kohler D, &, Matthys H, (1990) Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 141, 605-612.
119. Hirsh AJ, Zhang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA, Sabater JR, Abraham WM, Donowitz M, Cha B, et al,. (2008) Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl] butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 325, 77-88.
120. Butler R, Hunt T, &, Smith NJ, (2015) ENaC inhibitors for the treatment of cystic fibrosis. Pharm Pat Anal 4, 17-27.
121. Garcia-Caballero A, Rasmussen JE, Gaillard E, Watson MJ, Olsen JC, Donaldson SH, Stutts MJ, &, Tarran R, (2009) SPLUNC1 regulates airway surface liquid volume by protecting ENaC from proteolytic cleavage. Proc Natl Acad Sci USA 106, 11412-11417.
122. Almaca J, Faria D, Sousa M, Uliyakina I, Conrad C, Sirianant L, Clarke LA, Martins JP, Santos M, Heriche JK, et al,. (2013) High-content siRNA screen reveals global ENaC regulators and potential cystic fibrosis therapy targets. Cell 154, 1390-1400.
123. Knowles MR, Clarke LL, &, Boucher RC, (1991) Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 325, 533-538.
124. Caputo A, Caci E, Ferrera L, Pedemonte N, Barsanti C, Sondo E, Pfeffer U, Ravazzolo R, Zegarra-Moran O, &, Galietta LJ, (2008) TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science 322, 590-594.
125. Schroeder BC, Cheng T, Jan YN, &, Jan LY, (2008) Expression cloning of TMEM16A as a calcium-activated chloride channel subunit. Cell 134, 1019-1029.
126. Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, Park SP, Lee J, Lee B, Kim BM, et al,. (2008) TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature 455, 1210-1215.
127. Schreiber R, Uliyakina I, Kongsuphol P, Warth R, Mirza M, Martins JR, &, Kunzelmann K, (2010) Expression and function of epithelial anoctamins. J Biol Chem 285, 7838-7845.
128. Martins JR, Faria D, Kongsuphol P, Reisch B, Schreiber R, &, Kunzelmann K, (2011) Anoctamin 6 is an essential component of the outwardly rectifying chloride channel. Proc Natl Acad Sci USA 108, 18168-18172.
129. Namkung W, Yao Z, Finkbeiner WE, &, Verkman AS, (2011) Small-molecule activators of TMEM16A, a calcium-activated chloride channel, stimulate epithelial chloride secretion and intestinal contraction. FASEB J 25, 4048-4062.
130. Qi J, Wang Y, Liu Y, Zhang F, Guan B, &, Zhang H, (2014) Development and validation of HTS assay for screening the calcium-activated chloride channel modulators in TMEM16A stably expressed CHO cells. Anal Bioanal Chem 406, 1713-1721.
131. Ousingsawat J, Schreiber R, &, Kunzelmann K, (2012) Differential contribution of SLC26A9 to Cl(-) conductance in polarized and non-polarized epithelial cells. J Cell Physiol 227, 2323-2329.
132. Roth EK, Hirtz S, Duerr J, Wenning D, Eichler I, Seydewitz HH, Amaral MD, &, Mall MA, (2011) The K+ channel opener 1-EBIO potentiates residual function of mutant CFTR in rectal biopsies from cystic fibrosis patients. PLoS One 6, e24445.
133. Luciani A, Villella VR, Esposito S, Gavina M, Russo I, Silano M, Guido S, Pettoello-Mantovani M, Carnuccio R, Scholte B, et al,. (2012) Targeting autophagy as a novel strategy for facilitating the therapeutic action of potentiators on DeltaF508 cystic fibrosis transmembrane conductance regulator. Autophagy 8, 1657-1672.
134. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C, Gavina M, Pulze L, Giardino I, Pettoello-Mantovani M, et al,. (2010) Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 12, 863-875.
135. De Stefano D, Villella VR, Esposito S, Tosco A, Sepe A, De Gregorio F, Salvadori L, Grassia R, Leone CA, De Rosa G, et al,. (2014) Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation. Autophagy 10, 2053-2074.
136. Khan A, (2011) Cystic fibrosis drug ivacaftor offers patients new hope, Los Angeles Times, 2 November 2011. http://www.latimes.com/health/la-he-cystic-fibrosis-drug-20111103-story.html.